Afrezza market outlook brightens as diabetes demand rises

The Business Research Company says the Afrezza market is set for stronger growth through 2035, driven by rising diabetes cases, higher healthcare spending and broader acceptance of inhaled insulin. North America led the market in 2025, while Asia-Pacific is projected to grow the fastest.

Why it matters: - Afrezza is positioned as a needle-free insulin option for people with diabetes, which could make treatment easier for patients who struggle with injectable insulin. - Growing diabetes prevalence and higher healthcare spending are expanding the potential market for inhaled insulin therapies.

What happened: - The Business Research Company published its Afrezza Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Oct. 29, 2026. - The report says the Afrezza market has grown on the back of rising diabetes cases, approval of inhaled insulin products, patient preference for easier treatment options and early adoption in adult diabetes care. - The report forecasts faster growth ahead as type 2 diabetes expands and inhalation drug delivery gains wider acceptance. - The company also published a free sample of the market report and a full version of the report.

The details: - Afrezza is an inhalable insulin designed to help manage blood glucose levels in people with diabetes. - The drug is absorbed through the lungs and works quickly as a fast-acting alternative to injectable insulin. - Afrezza is used mainly to control postprandial hyperglycemia, the blood sugar spikes that happen after eating. - The report links market growth to rising obesity rates, sedentary lifestyles, poor diets, aging populations, urbanization, genetic factors and better diagnosis and awareness. - UK data cited in the report showed the share of people with type 1 diabetes receiving comprehensive care at GP practices rose from 35.2% in 2022 to 43.8% in 2023. - The report says higher healthcare spending also supports adoption because treatment costs include medication, devices and ongoing monitoring. - UK healthcare expenditure rose 5.6% nominally from 2022 to 2023, after a 0.9% rise in 2022, according to the Office for National Statistics. - Real-term spending on long-term health and social care rose 2.8% in 2022, according to the same source. - In 2025, North America held the largest share of the Afrezza market because of established healthcare systems and high diabetes prevalence. - The Asia-Pacific region is expected to post the fastest growth over the forecast period because of rising diabetes populations, improving healthcare infrastructure and greater acceptance of innovative therapies. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics.

Between the lines: - The report suggests Afrezza's growth story is less about a single product shift and more about the broader move toward easier, faster diabetes treatment. - The strongest demand signals are coming from regions where diabetes is rising and healthcare systems are becoming more able to support new therapies. - Needle-free delivery and post-meal glucose control are the main clinical hooks supporting future adoption.

What's next: - Wider physician familiarity with Afrezza could help expand use beyond current patient groups. - The report expects broader acceptance of inhalation drug delivery and improved safety data to support future growth. - The company points to continued interest in rapid-acting insulin alternatives and better patient compliance driven by convenience.

The bottom line: - Afrezza's market outlook is improving because diabetes care is shifting toward more convenient, fast-acting treatment options, and global demand is still rising.